Effect of simvastatin on the pharmacokinetics of anastrozole

Ting Bao; Amanda L. Blackford; Vered Stearns

doi:10.1007/s10549-011-1859-6

Effect of simvastatin on the pharmacokinetics of anastrozole

Ting Bao, Amanda L. Blackford, Vered Stearns

School of Medicine

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

We have prospectively tested the effects of simvastatin on the pharmacokinetics of anastrozole and on estrogen concentrations in postmenopausal women with hormone receptor-positive breast cancer who were receiving adjuvant anastrozole. Following 14 days of simvastatin, we did not observe a significant change in plasma concentrations of anastrozole or hydroxyanastrozole in nine evaluable women. Likewise, we did not observe any statistically significant change in serum concentrations of either estradiol, which remained in the undetectable range, or estrone sulfate. Simvastatin and anastrozole may be safely co-administered. Pharmacokinetic results suggest that simvastatin is not likely to compromise the activity of anastrozole.

Original language	English (US)
Pages (from-to)	709-711
Number of pages	3
Journal	Breast Cancer Research and Treatment
Volume	131
Issue number	2
DOIs	https://doi.org/10.1007/s10549-011-1859-6
State	Published - Jan 2012

Keywords

Anastrozole
Breast cancer
Chemoprevention
Simvastastin

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1007/s10549-011-1859-6

Cite this

@article{a5fed2af34f34c488a93b7fc157a8bbf,

title = "Effect of simvastatin on the pharmacokinetics of anastrozole",

abstract = "We have prospectively tested the effects of simvastatin on the pharmacokinetics of anastrozole and on estrogen concentrations in postmenopausal women with hormone receptor-positive breast cancer who were receiving adjuvant anastrozole. Following 14 days of simvastatin, we did not observe a significant change in plasma concentrations of anastrozole or hydroxyanastrozole in nine evaluable women. Likewise, we did not observe any statistically significant change in serum concentrations of either estradiol, which remained in the undetectable range, or estrone sulfate. Simvastatin and anastrozole may be safely co-administered. Pharmacokinetic results suggest that simvastatin is not likely to compromise the activity of anastrozole.",

keywords = "Anastrozole, Breast cancer, Chemoprevention, Simvastastin",

author = "Ting Bao and Blackford, {Amanda L.} and Vered Stearns",

note = "Funding Information: Acknowledgments The authors thank Dr. Elizabeth Folkerd and Professor Mitchell Dowsett for the determination of estrogen concentrations and interpretation of results. The authors thank Drs. Michelle A. Rudek and Zeruesenay Desta for measurements of anastrozole and metabolite concentrations and interpretation of results. The authors also thank Dr. John H. Fetting, Dr. Tatiana M. Prowel, Ms. Shannon A. Slater, Ms. Stacie C. Jeter, and Ms. Laurie A. Wright for their assistance with regulatory requirements and patient recruitment. This study was supported by the Breast Cancer Research Foundation (VS), and an ASCO Young Investigator Award (TB).",

year = "2012",

month = jan,

doi = "10.1007/s10549-011-1859-6",

language = "English (US)",

volume = "131",

pages = "709--711",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer New York",

number = "2",

}

TY - JOUR

T1 - Effect of simvastatin on the pharmacokinetics of anastrozole

AU - Bao, Ting

AU - Blackford, Amanda L.

AU - Stearns, Vered

N1 - Funding Information: Acknowledgments The authors thank Dr. Elizabeth Folkerd and Professor Mitchell Dowsett for the determination of estrogen concentrations and interpretation of results. The authors thank Drs. Michelle A. Rudek and Zeruesenay Desta for measurements of anastrozole and metabolite concentrations and interpretation of results. The authors also thank Dr. John H. Fetting, Dr. Tatiana M. Prowel, Ms. Shannon A. Slater, Ms. Stacie C. Jeter, and Ms. Laurie A. Wright for their assistance with regulatory requirements and patient recruitment. This study was supported by the Breast Cancer Research Foundation (VS), and an ASCO Young Investigator Award (TB).

PY - 2012/1

Y1 - 2012/1

N2 - We have prospectively tested the effects of simvastatin on the pharmacokinetics of anastrozole and on estrogen concentrations in postmenopausal women with hormone receptor-positive breast cancer who were receiving adjuvant anastrozole. Following 14 days of simvastatin, we did not observe a significant change in plasma concentrations of anastrozole or hydroxyanastrozole in nine evaluable women. Likewise, we did not observe any statistically significant change in serum concentrations of either estradiol, which remained in the undetectable range, or estrone sulfate. Simvastatin and anastrozole may be safely co-administered. Pharmacokinetic results suggest that simvastatin is not likely to compromise the activity of anastrozole.

AB - We have prospectively tested the effects of simvastatin on the pharmacokinetics of anastrozole and on estrogen concentrations in postmenopausal women with hormone receptor-positive breast cancer who were receiving adjuvant anastrozole. Following 14 days of simvastatin, we did not observe a significant change in plasma concentrations of anastrozole or hydroxyanastrozole in nine evaluable women. Likewise, we did not observe any statistically significant change in serum concentrations of either estradiol, which remained in the undetectable range, or estrone sulfate. Simvastatin and anastrozole may be safely co-administered. Pharmacokinetic results suggest that simvastatin is not likely to compromise the activity of anastrozole.

KW - Anastrozole

KW - Breast cancer

KW - Chemoprevention

KW - Simvastastin

UR - http://www.scopus.com/inward/record.url?scp=84856217967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856217967&partnerID=8YFLogxK

U2 - 10.1007/s10549-011-1859-6

DO - 10.1007/s10549-011-1859-6

M3 - Article

C2 - 22089963

AN - SCOPUS:84856217967

SN - 0167-6806

VL - 131

SP - 709

EP - 711

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 2

ER -

Effect of simvastatin on the pharmacokinetics of anastrozole

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this